U.K.-based CDMO Almac is adding to its U.S. operations with a new building at its site in North Carolina where it says it will house 100 new employees.

Israel-based Teva, whose pledge to unload manufacturing plants in its home country sparked strikes, is reportedly close to selling a site there.

China’s Zhejiang Huahai Pharmaceutical has been named in U.S. litigation after its valsartan API was found to contain a suspected carcinogen.

Another cell manufacturing facility will be built in the U.S., this by a transatlantic biotech in which GlaxoSmithKline owns a sizable share.

Bayer is laying off more than 225 workers at its complex in Berkeley, California, as it reorganizes manufacturing of its three hemophilia treatments.
…

Here is some other pharma manufacturing news of note for the week.

Manufacturing issues at a CMO and a missed forecast by Merck have led to a shortage of some of its Parkinson’s disease drug Sinemet.

It turns out it's not a good idea to kill the messenger, so to speak. As AmerisourceBergen found out, it can become an $885 million hit.